Relatlimab is a Monoclonal Antibody owned by Bristol-Myers Squibb, and is involved in 34 clinical trials, of which 5 were completed, and 29 are ongoing.

Relatlimab (BMS-986016) binds to LAG-3 on tumor infiltrating lymphocytes (TILs). This activates antigen-specific T-lymphocytes and enhances cytotoxic T cell-mediated tumor cell lysis, which would lead to a reduction in tumor growth. LAG-3 is a member of the immunoglobulin superfamily (IgSF) and binds to major histocompatibility complex (MHC) class II. The LAG-3 expression on TILs is associated with tumor-mediated immune suppression.

The revenue for Relatlimab is expected to reach a total of $23.8bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Relatlimab NPV Report.

Relatlimab was originated by Medarex and is currently owned by Bristol-Myers Squibb. Ono Pharmaceutical is the other company associated in development or marketing of Relatlimab.

Relatlimab Overview

Relatlimab (BMS-986016) is under development for the treatment of hematological malignancies, renal medullary carcinoma (RMC), newly diagnosed older acute myeloid leukemia, metastatic hepatocellular carcinoma (HCC), advanced unresectable or metastatic basal cell carcinoma, relapsed and refractory acute myeloid leukemia, non-Hodgkin lymphoma, relapsed refractory multiple myeloma, Hodgkin lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia (CLL), melanoma, multiple myeloma, gastric cancer, soft tissue sarcoma recurrent head and neck squamous cell carcinoma, non-small cell lung cancer, cervical cancer, ovarian cancer, bladder cancer, renal cell carcinoma, hepatocellular cancer, recurrent glioblastoma multiforme, gliosarcoma, colorectal cancer (solid tumors) and metastatic or unresectable melanoma (first line therapy). It is administered intravenously. It is a monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3), with potential immunomodulating and antineoplastic activities.

It was under development for solid tumors in Japan.

Bristol-Myers Squibb Overview

Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.

The company reported revenues of (US Dollars) US$46,385 million for the fiscal year ended December 2021 (FY2021), an increase of 9.1% over FY2020. The operating profit of the company was US$8,615 million in FY2021, compared to an operating loss of US$6,847 million in FY2020. The net profit of the company was US$6,994 million in FY2021, compared to a net loss of US$9,015 million in FY2020. The company reported revenues of US$11,218 million for the third quarter ended September 2022, a decrease of 5.6% over the previous quarter.

Quick View – Relatlimab

Report Segments
  • Innovator
Drug Name
  • Relatlimab
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Pre-Registration

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.